ArticleEClinicalMedicine2026
Motor function score changes in severe 5q spinal muscular atrophy during risdiplam treatment: an observational longitudinal nationwide cohort study.
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Spinal muscular atrophy (SMA) is caused by the loss of function of the Methods: Patients were screened for eligibility for risdiplam treatment between January and July 2021. We longitudinally evaluated motor scores during treatment up to 36 months using the Revised Upper Limb Module (RULM), the Adapted Test of Neuromuscular Disorders (ATEND), and hand strength tests. We assessed patient-reported Global Impression of Change (PGIC) after long-term treatment. Additionally, we investigated construct validity and responsiveness of ATEND as an additional outcome measure for severely affected patients. Findings: In this nationwide observational study, we analysed 72 patients with SMA types 1c and 2 (median age 29, IQR 23-42 years). We observed stabilised or improved RULM scores in 26 (43%) and increased ATEND scores in 33 (60%) patients after a median of 36 months of treatment. Eleven patients (18%) had a RULM score of 0 throughout treatment. ATEND score correlated strongly with RULM score supporting construct validity. After more than 3 years of treatment, 50 (89%) patients self-reported stability or improvement in overall wellbeing on the PGIC scale. Interpretation: Patients with SMA types 1 and 2 and severe motor impairment treated with risdiplam showed a deviation of the natural disease course of progressive motor score decline. The ATEND score is useful to monitor motor function change in severely affected patients. The majority of patients report improvement or stabilisation in motor function and overall wellbeing. Funding: None.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.